251 related articles for article (PubMed ID: 29572492)
1. Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1.
Rathore S; Akbari H; Rozycki M; Abdullah KG; Nasrallah MP; Binder ZA; Davuluri RV; Lustig RA; Dahmane N; Bilello M; O'Rourke DM; Davatzikos C
Sci Rep; 2018 Mar; 8(1):5087. PubMed ID: 29572492
[TBL] [Abstract][Full Text] [Related]
2. Radiomic features from the peritumoral brain parenchyma on treatment-naïve multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: Preliminary findings.
Prasanna P; Patel J; Partovi S; Madabhushi A; Tiwari P
Eur Radiol; 2017 Oct; 27(10):4188-4197. PubMed ID: 27778090
[TBL] [Abstract][Full Text] [Related]
3.
Bakas S; Akbari H; Pisapia J; Martinez-Lage M; Rozycki M; Rathore S; Dahmane N; O'Rourke DM; Davatzikos C
Clin Cancer Res; 2017 Aug; 23(16):4724-4734. PubMed ID: 28428190
[No Abstract] [Full Text] [Related]
4. Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma.
Kickingereder P; Neuberger U; Bonekamp D; Piechotta PL; Götz M; Wick A; Sill M; Kratz A; Shinohara RT; Jones DTW; Radbruch A; Muschelli J; Unterberg A; Debus J; Schlemmer HP; Herold-Mende C; Pfister S; von Deimling A; Wick W; Capper D; Maier-Hein KH; Bendszus M
Neuro Oncol; 2018 May; 20(6):848-857. PubMed ID: 29036412
[TBL] [Abstract][Full Text] [Related]
5. In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature.
Akbari H; Bakas S; Pisapia JM; Nasrallah MP; Rozycki M; Martinez-Lage M; Morrissette JJD; Dahmane N; O'Rourke DM; Davatzikos C
Neuro Oncol; 2018 Jul; 20(8):1068-1079. PubMed ID: 29617843
[TBL] [Abstract][Full Text] [Related]
6. Integrating imaging and genomic data for the discovery of distinct glioblastoma subtypes: a joint learning approach.
Guo J; Fathi Kazerooni A; Toorens E; Akbari H; Yu F; Sako C; Mamourian E; Shinohara RT; Koumenis C; Bagley SJ; Morrissette JJD; Binder ZA; Brem S; Mohan S; Lustig RA; O'Rourke DM; Ganguly T; Bakas S; Nasrallah MP; Davatzikos C
Sci Rep; 2024 Feb; 14(1):4922. PubMed ID: 38418494
[TBL] [Abstract][Full Text] [Related]
7. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
[TBL] [Abstract][Full Text] [Related]
8. Radiomic MRI Phenotyping of Glioblastoma: Improving Survival Prediction.
Bae S; Choi YS; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
Radiology; 2018 Dec; 289(3):797-806. PubMed ID: 30277442
[TBL] [Abstract][Full Text] [Related]
9. Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
Lasocki A; Tsui A; Gaillard F; Tacey M; Drummond K; Stuckey S
J Clin Neurosci; 2017 May; 39():170-175. PubMed ID: 28214089
[TBL] [Abstract][Full Text] [Related]
10. Magnetic Resonance Imaging Reveals a Pronounced Treatment Response of a Isocitrate Dehydrogenase- and B-Raf Proto-Oncogene-Wildtype Epithelioid Glioblastoma.
Werner JM; Brunn A; Fink GR; Galldiks N
World Neurosurg; 2019 Jul; 127():213-215. PubMed ID: 30974270
[TBL] [Abstract][Full Text] [Related]
11. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
[TBL] [Abstract][Full Text] [Related]
12. MR Imaging Characteristics Associate with Tumor-Associated Macrophages in Glioblastoma and Provide an Improved Signature for Survival Prognostication.
Zhou J; Reddy MV; Wilson BKJ; Blair DA; Taha A; Frampton CM; Eiholzer RA; Gan PYC; Ziad F; Thotathil Z; Kirs S; Hung NA; Royds JA; Slatter TL
AJNR Am J Neuroradiol; 2018 Feb; 39(2):252-259. PubMed ID: 29191871
[TBL] [Abstract][Full Text] [Related]
13. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
15. The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors.
Jaber M; Wölfer J; Ewelt C; Holling M; Hasselblatt M; Niederstadt T; Zoubi T; Weckesser M; Stummer W
Neurosurgery; 2016 Mar; 78(3):401-11; discussion 411. PubMed ID: 26366972
[TBL] [Abstract][Full Text] [Related]
16. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
[TBL] [Abstract][Full Text] [Related]
17. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma.
Ingrisch M; Schneider MJ; Nörenberg D; Negrao de Figueiredo G; Maier-Hein K; Suchorska B; Schüller U; Albert N; Brückmann H; Reiser M; Tonn JC; Ertl-Wagner B
Invest Radiol; 2017 Jun; 52(6):360-366. PubMed ID: 28079702
[TBL] [Abstract][Full Text] [Related]
18. Diffusion tensor imaging-based machine learning for IDH wild-type glioblastoma stratification to reveal the biological underpinning of radiomic features.
Wang Z; Guan F; Duan W; Guo Y; Pei D; Qiu Y; Wang M; Xing A; Liu Z; Yu B; Zheng H; Liu X; Yan D; Ji Y; Cheng J; Yan J; Zhang Z
CNS Neurosci Ther; 2023 Nov; 29(11):3339-3350. PubMed ID: 37222229
[TBL] [Abstract][Full Text] [Related]
19. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
[TBL] [Abstract][Full Text] [Related]
20. Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models.
Kickingereder P; Burth S; Wick A; Götz M; Eidel O; Schlemmer HP; Maier-Hein KH; Wick W; Bendszus M; Radbruch A; Bonekamp D
Radiology; 2016 Sep; 280(3):880-9. PubMed ID: 27326665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
